PROGRAM

Session 1. GDM Pharmacotherapy

1. Metformin in GDM: What do the data tell us?
   Janet Rowan (National Women’s Health, New Zealand)
2. Is there a role for glyburide in the treatment of GDM?
   Christina M. Scifres (Indiana University School of Medicine, USA)
3. Insulin therapy in GDM
   Eiji Kawasaki (Diabetes Center Shin-Koga Hospital, Japan)

Session 2. Clinical Study and Obstetrics

1. How has COVID 19 changed GDM screening
   David McIntyre (The University of Queensland, Australia)
2. Guidance on management of COVID 19 in pregnancy
   Liona Chiu Yee Poon (The Chinese University of Hong Kong, Hong Kong)
3. Assessment of fetal well-being in diabetic pregnancy
   Tomoaki Ikeda (Mie University Graduate School of Medicine, Japan)

Session 3. Preexisting Diabetes

1. EVOLVE study
   Elizabeth R. Mathiesen (University of Copenhagen / Rigshospitalet, Denmark)
2. Lessons from the CONCEPTT trial
   Helen R. Murphy (University of East Anglia, UK)
3. MITY trial
   Denice S. Feig (University of Toronto, Canada)

Session 4. Early GDM and Treatment

1. Biomarkers in diagnosis of GDM
   Martin Overgaard (Odense University Hospital, Denmark)
2. The TOBOGM trial
   David Simmons (Western Sydney University, Australia)
3. EMERGE trial
   Fidelma Dunne (College of Medicine Nursing and Health Sciences, National University of Ireland, Ireland / Current Chairperson IADPSG)

Session 5. HAPO Study and F/U Study

1. The HAPO study and development of IADPSG criteria
   Donald R. Coustan (Warren Alpert Medical School of Brown University, USA)
2. HAPO follow-up study: Long-term metabolic health after GDM
   Boyd E. Metzger (Emeritus Tom D Spies Professor of Nutrition and Metabolism,
   Northwestern University Feinberg School of Medicine, USA)
3. HAPO children follow up study
   Ronald C. Ma (The Chinese University of Hong Kong, Hong Kong)

Session 6. GDM and Obesity

1. DALI study
   Rosa Corcoy (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona,PI, CIBER-BBN, Spain)
2. Short and long term effects of obesity and excessive gestational weight gain in
   women and their children
   Patrick M. Catalano (Tufts University School of Medicine, USA)
3. The importance of core outcome sets in diabetes and pregnancy
   Aoife M. Egan (Mayo Clinic Rochester, USA)

Session 7. T2 DM Prevention

1. Prevention of type 2 diabetes – Experiences from the finnish diabetes prevention study
   Jaakko Tuomilehto (University of Helsinki, Finland)
2. Breastfeeding: Preventive effect against the development of diabetes in women with a history of GDM
   Ichiro Yasuhi (NHO Nagasaki Medical Center, Japan)
3. Lifestyle intervention using IoT devices and mobile apps for postpartum weight retention in obese pregnant women
   Naoko Arata (Center for Maternal-Fetal-Neonatal and Reproductive Medicine, National Center for Child Health and Development, Japan)

Session 8. Obstetrcis and Metabolism in Early Pregnancy

1. Longitudinal changes in insulin secretory response across pregnancy
   Camille E. Powe (Harvard Medical School, USA)
2. The human placenta in the first trimester of pregnancy: Effects of diabetes and obesity
   Gernot Desoye (Medical University of Graz Perinatal Research Laboratory, Austria)
3. Epigenetics in early life, which affects obesity in later life
   Koshi Hashimoto (Dokkyo Medical University Saitama Medical Center, Japan)

Special lecture: IADPSG Lifetime Achievement Award

The path I walked fully ―Foundation of the field of diabetes and pregnancy―
Yasue Omori (Emeritus Professor of Tokyo Women’s Medical University / Honorary Chairperson of the Japanese Society of Diabetes and Pregnancy, Japan)